ViroPharma Inc. (Nasdaq: VPHM) reported that its antivirus maribavir failed a late stage clinical trial sending shares of the biopharmaceutical plummeting $5.91 to $6.30.
ViroPharma's Antivirus Fails Study
February 09, 2009 at 12:52 PM EST
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.